VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | Insights into pemigatinib and the recent FDA approval of this agent

Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the recent FDA approval of pemigatinib for patients with FGFR1 rearranged relapsed/refractory (R/R) myeloid/lymphoid neoplasms. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter